Evaluation and eligibility of HLA-identical sibling donors for stem cell bone marrow donation

被引:2
|
作者
Morrison, AE
Green, RHA
Watson, DM
Franklin, IM
机构
[1] Glasgow Royal Infirm, Clin Apheresis Unit, Glasgow G4 0SF, Lanark, Scotland
[2] Law Hosp, Glasgow & West Scotland Blood Transfus Serv, Carluke ML8 5ES, Scotland
关键词
allogeneic transplantation; peripheral blood progenitor cells;
D O I
10.1046/j.1365-3148.1998.00151.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Overall, the number of allogeneic transplants performed world-wide has not increased dramatically over the past 5 years. However, the proportion of allogeneic transplants undertaken using peripheral blood progenitor cells (PBPCs) has risen significantly. Currently, as part of an ethically approved trial, potential donors are seen, assessed and consented by physicians not caring directly for the recipients. Thirty-five potential sibling donors were seen and assessed for their willingness and fitness to donate for 28 patients. One donor opted to give bone marrow and the rest selected PBPC donation. Seven of these donors were found to have concurrent medical conditions. Due to poor venous access, one donor was advised to donate bone marrow and two others donated bone marrow due to an underlying condition. Four others were deemed unfit for donation. Donation of stem cells from bone marrow or peripheral blood is not a risk-free procedure; careful preassessment and counselling is mandatory especially when the age of prospective patients and therefore donors is increasing.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 50 条
  • [31] Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants
    Michonneau, David
    Peffault de Latour, Regis
    Porcher, Raphael
    Robin, Marie
    Benbunan, Marc
    Rocha, Vanderson
    Ribaud, Patricia
    Ferry, Christele
    Devergie, Agnes
    Vanneaux, ValErie
    Gluckman, Eliane
    Marolleau, Jean Pierre
    Socie, Gerard
    Larghero, Jerome
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (01) : 107 - 114
  • [32] Association of pharmacogenes polymorphisms with toxicities and GvHD after HLA-identical sibling bone marrow transplantation.
    Rocha, V
    Porcher, R
    Filion, A
    Bittencourt, H
    Zanette, D
    Vilela, G
    Silva, WA
    Devergie, A
    Esperou, H
    Ribaud, P
    Socie, G
    Gluckman, E
    Zago, MA
    BLOOD, 2003, 102 (11) : 241A - 242A
  • [33] COMPARISON OF HLA-IDENTICAL SIBLING AND AUTOLOGOUS BONE-MARROW TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA (AML)
    KEATING, A
    ROWLINGS, PA
    HOROWITZ, MM
    DICKE, K
    GALE, RP
    KLEIN, JP
    BLOOD, 1994, 84 (10) : A201 - A201
  • [34] HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission
    Gale, RP
    Buchner, T
    Zhang, MJ
    Heinecke, A
    Champlin, RE
    Dicke, KA
    Gluckman, E
    Good, RA
    Gratwohl, A
    Herzig, RH
    Keating, A
    Klein, JP
    Marmont, AM
    Prentice, HG
    Rowlings, PA
    Sobocinski, KA
    Speck, B
    Weiner, RS
    Horowitz, MM
    LEUKEMIA, 1996, 10 (11) : 1687 - 1691
  • [35] Thalassemia - Incidence and predictive factors for chronic GVHD after HLA-identical sibling bone marrow transplantation
    Ghavamzadeh, A
    Alimoghaddam, K
    Bahar, B
    Foroughi, F
    BONE MARROW TRANSPLANTATION, 2002, 29 : S172 - S172
  • [36] Allogeneic bone marrow and peripheral blood stem cell transplantation (BMT/PBSCT) with HLA-non-identical sibling or unrelated donors.
    Blau, IW
    Basara, N
    Kirsten, D
    Rudolphi, M
    Römer, E
    Bischoff, M
    Grothaus, B
    Günzelmann, S
    Gengenbacher, D
    Schmetzer, B
    Kiehl, MG
    BLOOD, 1998, 92 (10) : 330B - 330B
  • [37] Hematopoietic stem cell transplantation: In patients above 40 years young HLA-matched unrelated donors should be preferred to HLA-identical sibling donors.
    Ottinger, HD
    Beelen, DW
    Elmaagacli, AH
    Peceny, R
    Grosse-Wilde, H
    BLOOD, 2003, 102 (11) : 489A - 489A
  • [38] ALLOGENEIC BONE-MARROW TRANSPLANTATION IN CHILDREN FROM OTHER THAN HLA-IDENTICAL SIBLING DONOR
    LOCATELLI, F
    BONGIORNO, M
    ZECCA, M
    GIANI, S
    GIORGIANI, G
    GUAGNINI, R
    MORANDI, P
    PORTA, F
    NESPOLI, L
    BURGIO, GR
    SEVERI, F
    BONE MARROW TRANSPLANTATION, 1991, 7 : 124 - 127
  • [39] Is There a Stronger Graft-Versus-Leukemia Effect Using HLA-Haplo-Identical Donors Compared to HLA-Identical Sibling Donors?
    Ringden, E.
    Labopin, Myriam
    Ciceri, Fabio
    Nagler, Arnon
    Mohty, Mohamad
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S348 - S348
  • [40] Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?
    Heimfeld, S
    LEUKEMIA, 2003, 17 (05) : 856 - 858